StockMarketWire.com - AstraZeneca said its small cell lung cancer drug had met its primary goal as it showed a 'clinically-meaningful' improvement in survival rates of patients suffering from the disease compared with chemotherapy alone.

A planned interim analysis conducted by an Independent Data Monitoring Committee concluded that the trial had met its primary endpoint by showing a 'statistically-significant and clinically-meaningful improvement in OS in patients treated with Imfinzi in combination with standard-of-care etoposide and platinum-based chemotherapy options versus chemotherapy alone,' the company said.

'The safety and tolerability for this Imfinzi combination was consistent with the known safety profiles of these medicines,' it added.






Story provided by StockMarketWire.com